|
THE JENEX CORPORATION ISSUES PROGRESS REPORT
March 22, 2006
Burlington, Ontario
THE JENEX CORPORATION (“Jenex” or the “Corporation”) (TSX Venture Exchange – JEN), is pleased to offer the following update relating to our interceptCS™ Canadian launch. The initial purchase orders have been received from Shoppers Drug Mart and product has been shipped into their distribution centres across the country. interceptCS will be available in Shoppers Drug Mart stores across Canada by the end of March. interceptCS can now be seen on the Shoppers Drug Mart website at (www.shoppersdrugmart.ca) The Canadian launch will be supported by a national advertising and public relations campaign, which will begin in the middle of April. The national campaign will include radio, print and inform and educate programs for consumers and health care professionals.
A new Jenex interceptCS website (www.interceptCS.com), designed to inform and educate consumers and health care professionals, will be available for viewing by March 28th.
About The Jenex Corporation
Headquartered in Burlington, Ontario, the Corporation owns a patented Thermal Therapy technology. Patents in the United States, Canada, Australia and Europe protect the technology. interceptCS is the first product proven and approved to prevent cold sores. Jenex has been approved to market interceptCS in Canada with its approved claim “For prevention and relief of the symptoms of herpes labialis (cold sores) such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks”. More information about the Corporation can be found at www.jenexcorp.com
Enquiries:
Michael A. Jenkins, President
The Jenex Corporation
940 Sheldon Court, Suite 207
Burlington, Ontario
L7L 5K6
Telephone: (905) 632-3830
Facsimile: (905) 632-3774
Email: jenex@jenexcorp.com
The TSX Venture Exchange has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.
|
